Document is current

Article History

Received: 30 September 2022

Accepted: 9 November 2022

First Online: 28 November 2022

Declarations

:

: SK, PB-B, CVdD, KK, GG, SS-M, CK, WV, and MW are members of RheumaDatenRhePort. SK received consulting fees or speaker’s fees from Abbvie, Berufsverband Deutscher Rheumatologen, Celgene, Novartis, Rheumaakademie, and Siemens Healthineers, participated on a data safety monitoring or advisory board for AbbVie and Novartis, and is involved in Novartis phase 3 studies. FS received consulting fees, speaker’s fees, or support from travel from AbbVie, Sanofi, and Novartis. PBB received speaking fees from AbbVie, Boehringer Ingelheim, Chugai/Roche, Janssen-Cilag, Lilly, Novartis, Pfizer, and UCB and participated on a data safety monitoring or advisory board for RHADAR GbR. SSM received speaking fees from AbbVie, BMS, Gilead, GSK, Janssen, Lilly, Novartis, Sanofi, and UCB. ME received fees from RHADAR GbR for statistical analyses and consultation services and received consulting fees or speaker’s fees from AbbVie, Chugai, Janssen, Roche, and Sanofi. WV received grants or contracts for development of digital eHealth systems from Verein zur Förderung der Rheumatologie e.V and honoraria for lectures and travel support from Novartis. MW received consulting fees, speaking fees, travel support, or advisory board support from AbbVie, Boehringer, Fresenius, Novartis, and Viatris. PR, MR, JW, PS, FP, CvdD, KK, GG, PW, CK, and GA do not have any competing interests to declare.

: The study protocol was approved by the regional ethics committee (Ethik-Kommission der Bayerischen Landesärztekammer, number 17053, approved 11 December 2017). Authors fulfilled the ICMJE authorship criteria.

: Written informed consent was obtained from all patients prior to study start.